30-Second Takeaway
- Persistent subtle IADL impairment strongly tracks Alzheimer biomarkers and sharply elevates dementia risk in dementia-free elders.
- Age-related Alzheimer pathology is very common; many cognitively normal older adults harbor biomarker evidence of disease.
- Simple performance and functional screens—modified SPPB, frailty, and basic ADLs—offer powerful risk stratification for surgery, mortality, and disability.
Week ending December 20, 2025
Functional red flags, frailty tools, and targeted interventions for late-life cognition, mobility, and survival
Persistent instrumental ADL impairment flags early Alzheimer pathology and high dementia risk
In 1000 dementia-free ADNI participants (mean age ~73, 63% with MCI), persistent impairment in three IADLs was closely linked to CSF Alzheimer biomarkers. Persistent, but not transient, difficulty with preparing a hot drink, cooking a balanced meal, and shopping alone tracked lower Aβ42 and higher p-tau181. APOE-ε4 carriage was more frequent with persistent impairment, aligning functional decline with genetic and biofluid evidence of Alzheimer pathology. Persistent impairment conferred a 6.66-fold higher dementia incidence versus no impairment; transient impairment showed only modest risk elevation.
Mobility-Fit boosts arm strength and quality of life in long-term care residents
This cluster RCT in 20 long-term care facilities randomized 146 residents (median age 86) to 12 weeks of Mobility-Fit or usual-care exercise. Mobility-Fit added tailored upper-limb and core resistance, balance, and agility training three times weekly, versus lower-limb–focused usual care. Compared with control, Mobility-Fit produced greater improvements in elbow extension strength and in EQ-5D utility and visual analogue quality-of-life scores. Both groups improved lower-limb strength, mobility, and questionnaire-based fall risk, reflecting benefits of structured physical activity.
Plasma p-tau217 data show Alzheimer pathology is common in community-dwelling elders
In a Norwegian population cohort of 11,486 adults ≥58, plasma p-tau217 was used as a surrogate for Alzheimer neuropathological change. Estimated Alzheimer pathology prevalence rose from <8% at ages 58–69.9 to 65.2% in those over 90 years. Among adults ≥70, 10% had preclinical Alzheimer disease, 10.4% prodromal disease, and 9.8% Alzheimer dementia based on clinical and biomarker status. Pathology was present in 60% of dementia, 32.6% of MCI, and 23.5% of cognitively unimpaired participants ≥70.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.